Anti-Tumor Effect of a Peptide Targeting HPV16 E7 in Cervical Cancer
Author Information
Author(s): Guo Cai-ping, Liu Ke-wei, Luo Hai-bo, Chen Hong-bo, Zheng Yi, Sun Shen-nan, Zhang Qian, Huang Laiqiang
Primary Institution: School of Life Sciences, Tsinghua University, Beijing, People's Republic of China
Hypothesis
Can a peptide antagonist of HPV16 E7 effectively inhibit the growth of HPV16-positive cervical cancer cells?
Conclusion
The peptide antagonist Pep-7 shows significant anti-tumor efficacy against HPV16-positive cervical cancer by disrupting the interaction between HPV16 E7 and the retinoblastoma protein.
Supporting Evidence
- The peptide Pep-7 significantly inhibited the proliferation of HPV16-positive cervical cancer cells in a dose-dependent manner.
- Pep-7 treatment led to G1 phase cell cycle arrest in SiHa cells.
- Animal studies showed that Pep-7 reduced tumor growth by up to 93.86% compared to control.
- Pep-7 disrupted the interaction between HPV16 E7 and the retinoblastoma protein, leading to increased pRb levels.
Takeaway
A special peptide can help stop cancer cells from growing by blocking a virus that makes them grow too fast.
Methodology
The study involved screening a phage display library for peptides that bind to HPV16 E7, followed by in vitro and in vivo testing of the selected peptide's effects on cell proliferation and tumor growth.
Statistical Information
P-Value
0.004
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website